Anika Therapeutics, Inc. (ANIK) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $28.77, down from yesterday’s close by -37.62%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Anika Therapeutics, Inc. (ANIK) currently trades with a market capitalization of $426.37 Million. That value represents a market adjusting for revenues that have been falling by -9.07 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of $25.1 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.33 on a per share basis this quarter. Perhaps, that suggests something about why 4.03% of the outstanding share supply is held by institutional investors.
We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Anika Therapeutics, Inc. recorded a 52-week high of $69.81. It is now trading 41.04% off that level. The stock is trading $41.85 its 50-day moving average by 13.08%. The stock carved out a 52-week low down at $30.91.
In recent action, Anika Therapeutics, Inc. (ANIK) has made a move of -26.14% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 13.48, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 14.98% with $14.41 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ANIK.